Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Invested Capital: 2020-2025

Historic Invested Capital for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $976.6 million.

  • Janux Therapeutics' Invested Capital rose 48.84% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 48.84%. This contributed to the annual value of $1.0 billion for FY2024, which is 197.02% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Invested Capital is $976.6 million, which was down 1.41% from $990.5 million recorded in Q2 2025.
  • Janux Therapeutics' Invested Capital's 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of $299.5 million in Q2 2023.
  • For the 3-year period, Janux Therapeutics' Invested Capital averaged around $661.4 million, with its median value being $656.1 million (2024).
  • As far as peak fluctuations go, Janux Therapeutics' Invested Capital soared by 2,602.58% in 2021, and later declined by 12.90% in 2023.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Invested Capital stood at $366.3 million in 2021, then fell by 12.44% to $320.7 million in 2022, then climbed by 7.36% to $344.3 million in 2023, then skyrocketed by 197.02% to $1.0 billion in 2024, then surged by 48.84% to $976.6 million in 2025.
  • Its last three reported values are $976.6 million in Q3 2025, $990.5 million for Q2 2025, and $1.0 billion during Q1 2025.